Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir for Prevention of Late CMV after Allo-HCT
NCT00016068Phase 3Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus infection (CMV) comparing Valganciclovir with Placebo (2 arms). Primary endpoints: Cytomegalovirus disease and non-CMV invasive infection-free survival at Day 270, Incidence of Cytomegalovirus disease at Day 270 and 2 more. Started Jan 2001; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00016068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016068.